Literature DB >> 26394669

A Paradoxical Treatment for a Paradoxical Condition: Infliximab Use in Three Cases of Mycobacterial IRIS.

Denise C Hsu1, Kimberly F Faldetta1, Luxin Pei1, Virginia Sheikh1, Netanya S Utay2, Gregg Roby1, Adam Rupert3, Anthony S Fauci1, Irini Sereti1.   

Abstract

The management of corticosteroid refractory immune reconstitution inflammatory syndrome (IRIS) is currently unclear. Infliximab administration was associated with clinical improvement without significant adverse events in 3 patients with mycobacterial IRIS. Immunologic and virologic responses to antiretroviral therapy were unaffected. Tumor necrosis factor blockade may be beneficial for IRIS and warrants further study in clinical trials. Published by Oxford University Press for the Infectious Diseases Society of America 2015. This work is written by (a) US Government employee(s) and is in the public domain in the US.

Entities:  

Keywords:  immune reconstitution inflammatory syndrome; infliximab; mycobacterial infection

Mesh：

Substances：

Year:  2015        PMID： 26394669      PMCID： PMC4690485          DOI： 10.1093/cid/civ841

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  15 in total

1.  The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement.

Authors:  I Solovic; M Sester; J J Gomez-Reino; H L Rieder; S Ehlers; H J Milburn; B Kampmann; B Hellmich; R Groves; S Schreiber; R S Wallis; G Sotgiu; E H Schölvinck; D Goletti; J P Zellweger; R Diel; L Carmona; F Bartalesi; P Ravn; A Bossink; R Duarte; C Erkens; J Clark; G B Migliori; C Lange
Journal:  Eur Respir J       Date:  2010-06-07       Impact factor: 16.671

2.  A life-threatening central nervous system-tuberculosis inflammatory reaction nonresponsive to corticosteroids and successfully controlled by infliximab in a young patient with a variant of juvenile idiopathic arthritis.

Authors:  Jaimes-Hernández Jorge; Cárdenas Graciela; Aranda-Pereira Pablo; Soto-Hernández José Luis
Journal:  J Clin Rheumatol       Date:  2012-06       Impact factor: 3.517

3.  Immune reconstitution to Mycobacterium tuberculosis after discontinuing infliximab.

Authors:  Robert Belknap; Randall Reves; William Burman
Journal:  Int J Tuberc Lung Dis       Date:  2005-09       Impact factor: 2.373

4.  Systemic steroid treatment of paradoxical upgrading reaction in patients with lymph node tuberculosis.

Authors:  Carolina Garcia Vidal; Javier Garau
Journal:  Clin Infect Dis       Date:  2005-09-15       Impact factor: 9.079

5.  Therapeutic use of infliximab in tuberculosis to control severe paradoxical reaction of the brain and lymph nodes.

Authors:  Timothy K Blackmore; Laurens Manning; William J Taylor; Robert S Wallis
Journal:  Clin Infect Dis       Date:  2008-11-15       Impact factor: 9.079

6.  Selective expansion of polyfunctional pathogen-specific CD4(+) T cells in HIV-1-infected patients with immune reconstitution inflammatory syndrome.

Authors:  Yolanda D Mahnke; Jamieson H Greenwald; Rebecca DerSimonian; Gregg Roby; Lis R V Antonelli; Alan Sher; Mario Roederer; Irini Sereti
Journal:  Blood       Date:  2012-01-04       Impact factor: 22.113

Review 7.  Biomarkers in immune reconstitution inflammatory syndrome: signals from pathogenesis.

Authors:  Irini Sereti; Alison J Rodger; Martyn A French
Journal:  Curr Opin HIV AIDS       Date:  2010-11       Impact factor: 4.283

8.  A patient with de novo tuberculosis during anti-tumor necrosis factor-alpha therapy illustrating diagnostic pitfalls and paradoxical response to treatment.

Authors:  Sandra M Arend; Eliane M S Leyten; Willeke P J Franken; Erik M Huisman; Jaap T van Dissel
Journal:  Clin Infect Dis       Date:  2007-10-25       Impact factor: 9.079

9.  A study of the safety, immunology, virology, and microbiology of adjunctive etanercept in HIV-1-associated tuberculosis.

Authors:  Robert S Wallis; Peter Kyambadde; John L Johnson; Libby Horter; Rodney Kittle; Monika Pohle; Constance Ducar; Monica Millard; Harriet Mayanja-Kizza; Christopher Whalen; Alphonse Okwera
Journal:  AIDS       Date:  2004-01-23       Impact factor: 4.177

10.  Adalimumab treatment of life-threatening tuberculosis.

Authors:  Robert S Wallis; Cloete van Vuuren; Samantha Potgieter
Journal:  Clin Infect Dis       Date:  2009-05-15       Impact factor: 9.079
View more
  15 in total

Review 1.  HIV infection and immune activation: the role of coinfections.

Authors:  Afroditi Boulougoura; Irini Sereti
Journal:  Curr Opin HIV AIDS       Date:  2016-03       Impact factor: 4.283

Review 2.  Immunosenescence and hurdles in the clinical management of older HIV-patients.

Authors:  Marco Ripa; Stefania Chiappetta; Giuseppe Tambussi
Journal:  Virulence       Date:  2017-02-21       Impact factor: 5.882

3.  Neurotuberculosis: Control of Steroid-Refractory Paradoxical Inflammatory Reaction With Ruxolitinib.

Authors:  Yingda L Xie; Fanny Ita-Nagy; Ray Y Chen; Maura M Manion; Irini Sereti; Luxin Pei; Steven M Holland
Journal:  Open Forum Infect Dis       Date:  2019-10-26       Impact factor: 3.835

Review 4.  Immune reconstitution inflammatory syndrome in HIV infection: taking the bad with the good.

Authors:  C-S Wong; E S Richards; L Pei; I Sereti
Journal:  Oral Dis       Date:  2016-12-23       Impact factor: 3.511

5.  Identification of rare HIV-1-infected patients with extreme CD4+ T cell decline despite ART-mediated viral suppression.

Authors:  Andrea Lisco; Chun-Shu Wong; Silvia Lucena Lage; Itzchak Levy; Jason Brophy; Jeffrey Lennox; Maura Manion; Megan V Anderson; Yolanda Mejia; Christopher Grivas; Harry Mystakelis; Peter D Burbelo; Ainhoa Perez-Diez; Adam Rupert; Craig A Martens; Sarah L Anzick; Caryn Morse; Shanna Chan; Claire Deleage; Irini Sereti
Journal:  JCI Insight       Date:  2019-04-18

6.  To Induce Immune Reconstitution Inflammatory Syndrome or Suppress It: The Spectrum of Mycobacterium genavense in the Antiretroviral Era.

Authors:  Maura Manion; Niamh Lynn; Luxin Pei; Dima A Hammoud; Elizabeth Laidlaw; Gregg Roby; Dorinda Metzger; Yolanda Mejia; Andrea Lisco; Adrian Zelazny; Steve Holland; Marie-Louise Vachon; Matthew Scherer; Colm Bergin; Irini Sereti
Journal:  Clin Infect Dis       Date:  2021-01-27       Impact factor: 9.079

7.  Robust Reconstitution of Tuberculosis-Specific Polyfunctional CD4+ T-Cell Responses and Rising Systemic Interleukin 6 in Paradoxical Tuberculosis-Associated Immune Reconstitution Inflammatory Syndrome.

Authors:  Shruthi Ravimohan; Neo Tamuhla; Kebatshabile Nfanyana; Andrew P Steenhoff; Rona Letlhogile; Ian Frank; Rob Roy MacGregor; Robert Gross; Drew Weissman; Gregory P Bisson
Journal:  Clin Infect Dis       Date:  2015-11-26       Impact factor: 9.079

8.  Immune reconstruction inflammatory syndrome in HIV infection: beyond what meets the eye.

Authors:  Irini Sereti
Journal:  Top Antivir Med       Date:  2020-01

Review 9.  Targeting immunometabolism in host defence against Mycobacterium tuberculosis.

Authors:  Frederick J Sheedy; Maziar Divangahi
Journal:  Immunology       Date:  2020-10-28       Impact factor: 7.397

10.  Plasma Metabolomics Reveals Dysregulated Metabolic Signatures in HIV-Associated Immune Reconstitution Inflammatory Syndrome.

Authors:  Luxin Pei; Kiyoshi F Fukutani; Rafael Tibúrcio; Adam Rupert; Eric W Dahlstrom; Frances Galindo; Elizabeth Laidlaw; Andrea Lisco; Maura Manion; Bruno B Andrade; Irini Sereti
Journal:  Front Immunol       Date:  2021-06-15       Impact factor: 7.561
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.